To analyze positive 3 patient distress MDHAQ (multidimensional health assessment questionnaire) screening indices, MAS2 (MDHAQ anxiety screen), MDS2 (MDHAQ depression screen), and FAST3F (fibromyalgia assessment screening tool), for possible elevations of rheumatoid arthritis (RA) activity/severity indices in routine care patients.

Articular cartilage can withstand substantial compressive and shear forces within the joint and also reduces friction during motion. The exceptional mechanical properties of articular cartilage stem from its highly organized extracellular matrix (ECM). The ECM is composed mainly of collagen type II and is pivotal in conferring mechanical durability to the tissue within its proteoglycan-rich matrix. Articular cartilage is prone to injury and degeneration, and current treatments often fail to restore the mechanical function of this tissue. A key challenge is replicating the intricate collagen-proteoglycan network, which is essential for the long-lasting restoration and mechanical durability of the tissue. Understanding articular cartilage development, which arises between late embryonic and early juvenile development, is vital for the creation of durable therapeutic strategies. The development of the articular ECM involves the biosynthesis, fibrillogenesis and self-assembly of the collagen type II network, which, along with proteoglycans and minor ECM components, shapes the architecture of adult articular cartilage. A deeper understanding of these processes could inform biomaterial-based therapies aimed at improving therapeutic outcomes. Emerging biofabrication technologies offer new opportunities to integrate developmental principles into the creation of durable articular cartilage implants. Bridging fundamental biology with innovative engineering offers novel approaches to generating more-durable 3D implants for articular cartilage restoration.

Cognitive impairment among patients with systemic lupus erythematosus (SLE) can significantly impact quality of life (QoL). This study aimed to determine the prevalence of cognitive impairment in SLE patients using the Montreal Cognitive Assessment Indonesian version (MoCA-INA) and to assess its association with QoL.

Anti-synthetase syndrome is a rare autoimmune disorder characterised by the presence of autoantibodies against aminoacyl transfer RNA synthetases. We report a unique case of a 54-year-old woman with anti-OJ anti-synthetase syndrome, characterised by the atypical occurrence of digital vasculitis in conjunction with the classic manifestations of anti-synthetase syndrome. Our patient presented with digital vasculitis affecting the right third and fourth fingers, rapidly evolving interstitial lung disease of the organising pneumonia subtype, sub-clinical myositis, arthritis and mechanic's hands. Notably, she had no prior history of Raynaud's phenomenon. Serological tests revealed positive anti-OJ antibodies and weakly positive anti-MI2 antibodies. Our patient's condition was managed with intravenous methylprednisolone then after stepped down to prednisolone and mycophenolate mofetil with successful therapeutic response.Current literature primarily highlights Raynaud's phenomenon and vasculopathy-related ischemia, whether occlusive or non-occlusive in anti-synthetase syndrome. This case study identifies digital vasculitis as a distinctive complication of anti-synthetase syndrome, anti-OJ subtype. It emphasises the importance of recognising vascular complications, including vasculitis, even when classic signs like Raynaud's phenomenon are absent. Further research is crucial to fully understand the range of vascular manifestations associated with anti-synthetase syndrome.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but frequently cause immune-related adverse events (IrAEs). ICI-induced large vessel vasculitis (LVV) is a rare IrAE, with limited available data. We aimed to describe and compare clinical characteristics and evolution of ICI-induced LVV to primary LVV.

Ozoralizumab (OZR) is a next-generation anti-TNF NANOBODY® compound. The primary objective was to evaluate the efficacy of OZR in patients with rheumatoid arthritis (RA) in varying rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) titres. The secondary objective was to evaluate the changes in RF and ACPA titres following OZR treatment.

To evaluate the efficacy, safety, and immunological effects of tofacitinib in patients with Sjögren's Disease (SjD), focusing on its impact on disease activity and immune cell modulation.

To identify key molecules involved in the disease pathophysiology of systemic vasculitis through trans-omics analysis, with a specific focus on demonstrating MMP12 as a potential biomarker in rheumatic entities.

Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by microvascular injury and impaired angiogenesis, with endothelial progenitor cells (EPCs) playing a key role in vascular repair. EPC subsets, including endothelial colony-forming cells (ECFCs) and colony-forming unit-endothelial cells (CFU-ECs), are known to be dysfunctional in SSc, contributing to disease-associated vasculopathy. Prostaglandin E1 (PGE1) is a vasodilator with potential pro-angiogenic effects, but its impact on EPC numbers and function in SSc remains unexplored. This study aimed to investigate whether PGE1 treatment can modulate EPC numbers, specifically CFU-ECs and ECFCs, in patients with SSc and Raynaud's phenomenon (RP), and evaluate its potential role in promoting vascular repair. Methods: This study evaluated the effect of PGE1 on EPC levels in 12 SSc patients with Raynaud's phenomenon (RP) and 5 healthy controls (HCs). CFU-EC and ECFC clusters were quantified before and after PGE1 treatment using standardized culture methods. PGE1 was administered intravenously over 8-9 days. Statistical analyses compared EPC counts between groups and time points.

Approximately half of individuals with suspected polymyalgia rheumatica (PMR) initiate prednisolone before rheumatological evaluation, but it is unknown if prednisolone reduces the ability to diagnose PMR. This study evaluated the clinical assessment of a PMR diagnosis before and after prednisolone initiation and after short-term prednisolone discontinuation.

To evaluate the incremental value of contrast-enhanced vascular MRI for also detecting inflammatory musculoskeletal manifestations in patients with GCA-PMR spectrum disease (GPSD).